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The Journal of Immunology
Treml4, an Ig Superfamily Member, Mediates Presentation of
Several Antigens to T Cells In Vivo, Including Protective
Immunity to HER2 Protein
Hiroaki Hemmi,*,†,‡,1 Neeha Zaidi,*,1 Bei Wang,*,1 Ines Matos,* Christopher Fiorese,*
Ashira Lubkin,* Lori Zbytnuik,* Koji Suda,*,x Kenneth Zhang,* Masaki Noda,{,‖,#
Tsuneyasu Kaisho,†,‡ Ralph M. Steinman,*,2 and Juliana Idoyaga*,2
Members of the triggering expressed on myeloid cells (Trem) receptor family fine-tune inflammatory responses. We previously
identified one of these receptors, called Treml4, expressed mainly in the spleen, as well as at high levels by CD8a+ dendritic cells
and macrophages. Like other Trem family members, Treml4 has an Ig-like extracellular domain and a short cytoplasmic tail that
associates with the adaptor DAP12. To follow up on our initial results that Treml4-Fc fusion proteins bind necrotic cells, we
generated a knockout mouse to assess the role of Treml4 in the uptake and presentation of dying cells in vivo. Loss of Treml4
expression did not impair uptake of dying cells by CD8a+ dendritic cells or cross-presentation of cell-associated Ag to CD8+
T cells, suggesting overlapping function between Treml4 and other receptors in vivo. To further investigate Treml4 function, we
took advantage of a newly generated mAb against Treml4 and engineered its H chain to express three different Ags (i.e., OVA,
HIV GAGp24, and the extracellular domain of the breast cancer protein HER2). OVA directed to Treml4 was efficiently presented
to CD8+ and CD4+ T cells in vivo. Anti–Treml4-GAGp24 mAbs, given along with a maturation stimulus, induced Th1 Ag-specific
responses that were not observed in Treml4 knockout mice. Also, HER2 targeting using anti-Treml4 mAbs elicited combined
CD4+ and CD8+ T cell immunity, and both T cells participated in resistance to a transplantable tumor. Therefore, Treml4
participates in Ag presentation in vivo, and targeting Ags with anti-Treml4 Abs enhances immunization of otherwise naive
mice. The Journal of Immunology, 2012, 188: 1147–1155.
O
ne feature of dendritic cells (DCs) and macrophages is
their capacity to take up dying cells, including necrotic
and apoptotic cells (1, 2). The uptake of dying cells and
presentation of cell-associated Ags to CD4+ Th cells and CD8+
T cells (cross-presentation) play crucial roles in the host’s
responses for induction of immunity or tolerance (3). Thus, the
identification of receptors that mediate binding of dead cells
represents a central challenge. We previously identified one of
these receptors, called Treml4 (4). Treml4, like many other mem-
bers of the triggering expressed on myeloid cells (Trem) fam-
ily, is characterized by the presence of an Ig-like extracellular
domain (ECD) and a short cytoplasmic tail that associates with the
adaptor molecule DAP12 (5).
Members of the Trem family are known to be involved in fine-
tuning of inflammatory responses (6). Accordingly, Trem1 acts
synergistically with TLRs to trigger the production of cytokines
(7). Also, Trem2 is involved in the clearance of apoptotic neurons
and production of cytokines by macrophages (8–10), and loss-of-
function mutations in human TREM2 or DAP12 cause Nasu–
Hakola disease, which is characterized by dementia and bone
cysts (11, 12). The function of Treml4 in vivo remains to be
elucidated. We previously found that a chimeric fusion protein,
consisting of the extracellular portion of Treml4 and a human
IgG1 Fc domain, binds dead cells positive for Annexin V and
propidium iodide (4). To extend this finding, but in an intact an-
imal, we generated a Treml4 knockout (KO) mouse. Interestingly,
Treml4 loss did not result in impaired uptake of dying cells or
inability to cross-present cell-associated Ags to CD8+ T cells,
suggesting overlapping functions between Treml4 and other re-
ceptors for dying cells.
Our original data revealed that Treml4, both at the mRNA and
protein levels, is mainly expressed in the spleen (4). We extended
these results and performed careful phenotyping of splenic leu-
kocyte populations by flow cytometry using a newly developed Ab
against Treml4 (4). Taking advantage of this mAb, we further
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found that anti-Treml4 mAb binds to appropriate DC, macro-
phage, and monocyte subsets in the spleen. Also, we considered
whether Treml4 has the capacity to initiate Ag uptake, processing,
and presentation on MHC class I and II using a novel approach
that involves delivery of Ags coupled to mAbs. This approach was
shown to increase the efficiency of Ag presentation on MHC class
I and II molecules ∼100-fold, and it allows T cell immunization
(13–15). However, many of the receptors targeted to date belong
to the C-type lectin family, which are probably involved in the
physiological capture of pathogens and subsequent Ag presenta-
tion. In this study we show with three different protein Ags that,
similar to C-type lectin receptors, an Ig superfamily member
called Treml4 can bring about Ag presentation and priming of
CD4+ and CD8+ T cells in vivo.
Materials and Methods
Mice
We purchased C57BL/6J (B6), BALB/cJ, and FVB/NJ mice from The
Jackson Laboratory. BALB/c 3 C57BL/6 (CxB6) F1 mice were from
Harlan. OVA-specific TCR transgenic mice OT-I (C57BL/6-Tg(TcraTcrb)
1100Mjb/J) and OT-II (C57BL/6-Tg(TcraTcrb)425Cbn/J), and TAP2/2
(B6.129S2-Taptm1Arp/J) mice were obtained from The Jackson Laboratory
and crossed, when necessary, to CD45.1 mice in house. The targeting
vector for Treml4 KO mice was designed by replacing a 1.7-kb fragment
including exon 1 and 2 with an ACN cassette. The ACN cassette contains
the neomycin resistance gene under the control of RNA polymerase II
promoter and Cre recombinase gene under the control of angiotensin-
converting enzyme promoter, flanked by loxP sites (16). Cre-mediated
recombination during spermatogenesis removed the cassette, leaving one
loxP (Fig. 1A). The targeting construct was transfected into B6 embryonic
stem (ES) cells (CY2.4). Targeted ES cells were screened by Southern
blotting and subsequently injected into B6 blastocysts. The resulting male
chimeric mice were bred to female B6 or C57BL/6-Tyrc-2J mice to obtain
germline transmission. All mice were maintained under specific pathogen-
free conditions and used at 6–8 wks of age, in accordance with The
Rockefeller University Animal Care and Use Committee guidelines.
Reagents
mAbs to Treml4 (16E5 and 32D11) (4), OLLAS peptide (17), CD4 (GK
1.5), CD8 (2.43), CD40 (IC10), and control Ig (GL117) (18) were pro-
duced from hybridoma supernatants, purified on protein G (GE Healthcare
Bio-Sciences, Piscataway, NJ), and when necessary, labeled with Alexa
Fluor 647 (Invitrogen, Carlsbad, CA) or EZ-Link Biotin (Pierce, Rockford,
IL), per the manufacturer’s instructions. The following fluorescent-con-
jugated mAbs were purchased from eBioscience (San Diego, CA) or BD
Pharmingen (San Diego, CA): FITC anti-B220 (RA3-6B2) and anti-Ly6G
(1A8), PE anti-CD115 (AFS98) and anti-CD11b (M1/70), PerCP-Cy5.5
anti-CD8a (53-6.7) and anti-F4/80 (BM8), PE-Cy7 anti-Ter119 (TER-
119), anti–TNF-a (MP6-XT22) and anti-CD19 (1D3), allophycocyanin-
eFluor 780 anti-CD11b (M1/70), Alexa Fluor 488 anti–IL-2 (JES6-5H4),
eFluor 450 and Alexa Fluor 700 anti-CD3ε (500A2), Alexa Fluor 700
and PerCP-Cy5.5 anti-CD4 (RM4-5), Alexa Fluor 488 and allophyco-
cyanin-eFluor 780 anti-CD11c (N418), PE-Cy7 and PE anti-CD49b
(DX5), and PE, allophycocyanin, and PE-Cy7 anti–IFN-g (XMG1.2).
PE anti–PDCA-1 (JF05-1C2.4.1) was from Miltenyi Biotec. Other re-
agents were Live/Dead Fixable Aqua or Violet vitality dye from Invitrogen,
DAPI (Sigma-Aldrich, St. Louis, MO), and CFSE (Invitrogen). Overlap-
ping (staggered by 4 aa) 15-mer peptides covering the entire HIV-GAGp17,
HIV-GAGp24, the ECD of the breast cancer protein HER2 or neu, or the
OVA peptide (aa 257–264, SIINFEKL) were synthesized by H. Zebroski
in the Proteomics Resource Center of The Rockefeller University.
Tumor cell line
The neu-expressing mammary tumor cell line NT2.5 was derived from
a spontaneous mammary tumor in female neu-N mice (FVB/N back-
ground) (19). The cell line was established and kindly provided by Dr.
E.M. Jaffee (The Johns Hopkins University School of Medicine, Balti-
more, Maryland). NT2.5 tumor cells were grown in a previously defined
Breast Media, which consisted of RPMI 1640 (Life Technologies, Invitro-
gen) with 20% FBS (Life Technologies, Invitrogen), 1% L-glutamine, 1%
nonessential amino acids, 1% Na-pyruvate, 0.5% penicillin/streptomycin,
0.02% gentamicin (Life Technologies, Invitrogen), and 0.2% insulin
(Sigma-Aldrich) and was maintained at 37˚C in 5% CO2.
Cloning, engineering, and production of anti-receptor mAbs
The V regions of anti-Treml4 mAbs (4) were cloned from RNAs of the
32D11 hybridoma with the 59 RACE. In brief, we used 59 phosphorylated
rat IgG1-specific oligonucleotides (59-GTC ATT TAC CCG GAG-39) or rat
k-specific oligonucleotides (59-GTC TAA CAC TCA TTC-39) to synthe-
size first-strand cDNAs using the Superscript III first-strand Synthesis
System (Invitrogen). After circularization of the cDNAs with RNA ligase
(Promega, Madison, WI), PCR was performed, and then the products were
cloned and sequenced. Primers used to amplify IgG1 H chain cDNA were
59-GCT CAATGG CAG GAC GTT CAG ATG-39 and 59-CTT GTC CAC
CTT GGT GCT GCT GGC-39, and for k L chain were 59-GTA CAG CAT
GAG CAG CAC CCT CTC-39 and 59-GTT CAT GAG GCA CAC GAC
TGA GGC-39. DNA for OVA, HIV GAGp24 (aa 133–363 derived from
HIV isolate BH10), and HER2 (aa 22–653) was cloned in frame into the C
terminus of the H chain of anti–mouse-DEC205, -Treml4, and control Ig,
as previously described (15, 20). An OLLAS epitope sequence was
inserted between the H chain and OVA (20), whereas a small linker se-
quence was inserted between the H chain and HIV GAGp24 or HER2
sequences (B. Wang, N. Zaidi, L.Z. He, K. Zhang, J.M.Y. Kuroiwa,
T. Keler, and R.M. Steinman, submitted for publication) (15, 18). Fusion
mAbs were expressed by transient transfection (calcium phosphate) in
293T cells in serum-free DMEM supplemented with Nutridoma SP
(Roche, Indianapolis, IN). The mAbs were purified on protein G columns
(GE Healthcare Bio-Sciences) and characterized by SDS/PAGE and
Western blotting using anti-mouse IgG1-HRP (Southern Biotech, Bir-
mingham, AL), HRP–anti-GAGp24 (ImmunoDiagnostics, Woburn, MA),
HRP–anti-OVA (Research Diagnostics), biotin–anti-HER2 (clone 42;
BD Transduction Laboratories, San Jose, CA), and biotin–anti-OLLAS
(produced in house), followed by HRP-conjugated streptavidin (Jackson
ImmunoResearch, West Grove, PA). Receptor binding was verified using
CHO-transfected cells by FACS analysis staining with Alexa Fluor 647-
labeled anti-OLLAS, PE-conjugated goat anti-mouse IgG (Jackson Im-
munoResearch), or Alexa Fluor 488-conjugated anti-HER2 mAb (clone
24D2; BioLegend, San Diego, CA).
Cell preparation
For analysis of different leukocyte populations, spleens were cut into small
pieces and incubated in a Hanks buffer (Life Technologies) solution
containing 400 U/ml Collagenase D (Roche) and 50 mg/ml DNase I
(Roche) for 25 min at 37˚C. Five millimolar of EDTA (Life Technologies)
was added for the last 5 min of incubation, and the cell suspension was
passed through a 70-mm cell strainer. In some experiments, cells were
enriched by negative selection using anti-CD19 magnetic beads and passed
through LS columns (Miltenyi Biotec, Auburn, CA). For analysis of in-
tracellular cytokine production by T cells, spleens were force-passed
through a 70-mm cell strainer to obtain a homogeneous cell suspension
without enzymatic digestion. RBCs were lysed by incubating with RBC
Lysis Buffer (BioWhittaker, Walkersville, MD) for 1 min. In some ex-
periments, splenocytes were labeled with CFSE to evaluate proliferation
capacity of primed T cells (14). In brief, bulk splenocytes (1 3 107 cells/
ml) were labeled with 1 mM CFSE (Invitrogen) at 37˚C for 10 min. CFSE-
labeled T cells were then restimulated with 0.1 mg/ml reactive or nonre-
active peptide mix for 4 d; subsequently, they were restimulated with 1 mg/
ml reactive peptide mix for another 6 h in the presence of brefeldin A
(BFA; 10 mg/ml; Sigma-Aldrich) for evaluation of intracellular cytokines.
For analysis of blood monocytes, mice were bled from the retro-orbital
vein, and leukocytes were enriched using Lympholyte-Mammal (Cedar-
lane Laboratories, Burlington, NC), following the manufacturer’s instruc-
tions.
Adoptive transfer and in vivo T cell-proliferation responses
OVA-specific transgenic CD8+ or CD4+ T cells were purified from lymph
nodes (LNs) and spleen cell suspensions of OT-I and OT-II mice, re-
spectively, by negative selection using anti-F4/80, anti-MHCII (TIB120),
anti-B220 (RA3-6B2), anti-NK1.1 (PK136), and anti-CD4 (GK1.5, for OT-
I preparation) or anti-CD8 (2.43, for OT-II preparation). T cell prolifera-
tion was evaluated by injecting individual animals with either 2–3 3 106
OT-I cells or 3-5 3 106 OT-II cells, labeled at 107/ml with 5 mM CFSE
(Invitrogen) for 10 min at 37˚C. Twenty-four hours later, 3 mg anti-
receptor mAbs conjugated with OVA were injected s.c. into the footpad.
CFSE dilution was evaluated 3 d later by FACS of spleen and pooled skin-
draining LNs (popliteal, inguinal, axillary, brachial, and cervical) after
surface staining for CD4 (OT-II) or CD8 (OT-I) and Va2 (OVA-specific
TCR; clone B20.1). Fold clonal expansion of transgenic T cells was cal-
culated as the ratio of the number of cells with more than one division/
number of undivided cells in the control group, as previously described (20).
















Uptake of dying cells and cross-presentation assay
To evaluate uptake of dying cells, splenocytes from B6 mice were labeled
with 5 mM CFSE for 10 min at 37˚C and then induced to undergo apo-
ptosis by osmotic shock (21). A total of 2 3 107 CFSE-labeled dying cells
was inoculated i.v. for 2 h; subsequently, spleens were collected, digested
with Collagenase D, and analyzed by FACS for DCs containing CFSE. To
measure presentation of cell-associated Ags, mice were similarly injected
with 2 3 107 OVA-pulsed and osmotically shocked TAP2/2 splenocytes
(TAP2/2/OVA), with or without 2S, 3S, 4R-1-O(a-galactopyranosyl)-2(N-
hexacosanoylamino)-1,3,4-octadecanetriol (a-GalCer) as adjuvant (22).
Immune responses to OVA were measured 1 wk later by restimulating
splenocytes for 6–12 h with OVA peptide (SIINFEKL) in the presence of
BFA (23).
Mice inoculations
Mice were immunized i.p. once with fusion mAbs with a stimulus for DC
maturation, which was 50 mg polyinosinic-polycytidylic acid (poly-IC;
InVivoGen, San Diego) together with 25 mg IC10 agonistic anti-CD40
mAb (15). In other experiments, we used a prime/boost regimen in
which anti-CD40 was omitted and 50 mg poly-IC (Thermo Scientific,
Waltham, MA) or poly-L-lysine and carboxymethylcellulose stabilized
poly-IC (Oncovir, Washington, DC) was the adjuvant for both prime and
boost immunizations given 1 mo apart. In tumor-protection experiments,
10 d after the vaccine boost (day 38), mice were inoculated s.c. with 1 3
106 NT2.5 neu-expressing tumor cells in the shaved right flank. Tumor size
was measured three times every week using a caliper. Tumor volumes were
estimated according to the formula: length 3 (width)2 3 0.5. When
animals seemed stressed or exhibited tumor ulceration or the tumor
diameters exceeded 12 mm, the mice were sacrificed, and this was
recorded as the date of death. For Ab depletion, 200 mg anti-CD4 (GK1.5)
or anti-CD8 (2.43) mAb or both were given to mice i.p. after boost im-
munization at 9, 6, and 3 d prior to tumor challenge. Rat IgG (GL117) was
given as the control mAb. Efficiency of depletion, defined as a reduction
.90% of the targeting cell subsets, was confirmed by FACS analysis of
peripheral blood cells. For in vivo-targeting experiments, mice were
injected i.p. for 1 h with 10 mg anti-Treml4 mAb labeled with Alexa Fluor
647.
Intracellular cytokine staining
Bulk splenocytes were restimulated with 15-mer peptide mix from HIV
GAGp24 (1 mg/ml), nonreactive HIV GAGp17 (1 mg/ml), the ECD of
HER2, or neu peptides (1 mg/ml) in the presence of 2 mg/ml costimulatory
anti-CD28 (clone 37.51; American Type Culture Collection) for 6 h at 37˚C,
adding 10 mg/ml BFA for the last 5 h to allow accumulation of intracellular
cytokines. Cells were washed, incubated for 10 min at 4˚C with 2.4G2
mAb (American Type Culture Collection) to block FcgRs, and stained
with mAbs against surface molecules for 20 min at 4˚C. Cells were then
fixed, permeabilized (Cytofix/Cytoperm; BD Biosciences), and stained
with mAbs against cytokines. A total of 1–3 3 105 live CD3+ cells was ac-
quired on a BD LSR II flow cytometer, and data were analyzed with
FlowJo Software (Tree Star, San Carlos, CA).
FIGURE 1. Generation of Treml4 KO mice. A, Schematic diagram of the mouse Treml4 WT allele, targeting vector, mutated allele in ES cells, and
mutated allele in Treml4-deficient mice. Filled and open boxes denote coding exons and noncoding exons, respectively. B, Southern blot analysis of
offspring from the heterozygote intercrosses. Genomic DNAwas extracted from mouse tails, digested with SphI, electrophoresed, and hybridized with the
radiolabeled probe indicated in A. WT and mutated alleles of Treml4 gene were at 9.1- and 7.4-kb, respectively. C, Northern blot analysis of whole
splenocytes. Total RNA (10 mg) was electrophoresed, transferred to a nylon membrane, and hybridized with Treml4 cDNA or b-actin cDNA fragment as
a probe. D, Representative data of the immunoblot signals for Treml4 in B6 WT and Treml4 KO mice. Spleens were lysed, 25 mg total protein was
separated by SDS-PAGE, and Treml4 expression was assayed by Western blot using anti-Treml4 mAb, followed by peroxidase-conjugated anti-rat mAb. To
control for protein loading, the membrane was incubated with stripping buffer and immunoblotted with anti–actin-HRP mAb. One experiment is repre-
sentative of two with similar results. E, Uptake of dying cells by DCs. A total of 20 3 106 CFSE-labeled dying splenocytes was injected i.v. to WT
littermates (Treml4+) or Treml4 KO (Treml42/2) mice. Two hours after injection, spleens were harvested, and uptake of CFSE+ cells was monitored in
CD8a+ and CD8a2 DC subsets. Plots show CD11chigh-gated cells and are representative of two independent experiments. F, Cross-presentation of cell-
associated Ag. Control littermates (Treml4+) or Treml4 KO (Treml42/2) mice were immunized i.v. with 20 3 106 dying TAP2/2 splenocytes loaded with
OVA (TAP2/2/OVA), in the presence or absence of the adjuvant a-GalCer. Seven days later, splenocytes from immunized mice were restimulated with
OVA peptide (SIINFEKL) for 12 h with BFA, and the presence of CD8+ T cells producing IFN-g was evaluated by flow cytometry after intracellular
cytokine staining. Plots shown CD3ε+-gated T cells. G, As in F, but the percentage of IFN-g+ CD8+ T cells of CD3ε+ splenocytes is shown as the mean of
three independent experiments. Each symbol represents an individual mouse, and the horizontal line denotes the mean.

















B6 or Treml4 KO mice were inoculated i.p. with 25 mg purified anti-
Treml4 mAb 3 h later, and spleens were harvested and frozen (280˚C)
in Tissue-Tek OCT (Sayura). Ten- to twelve-micrometer spleen sections
were fixed for 15 min in cold acetone, rehydrated in PBS, and blocked
with 5% mouse serum in FACS buffer (PBS/2% FBS) for 1 h at room
temperature. Sections were stained in a humidified chamber overnight at
4˚C with anti-rat Alexa Fluor 555 (Invitrogen), washed in FACS buffer,
incubated for 1 h at room temperature with 5% rat serum to block free
arms of primary mAb, and stained with secondary mAb. Marginal met-
allophilic macrophages were detected with FITC-labeled anti-CD169
(AbD Serotec), followed by anti-FITC Alexa Fluor 488 (Invitrogen).
Marginal zone macrophages were stained with purified with anti–SIGNR1
(in house), followed by anti-hamster FITC (Jackson ImmunoResearch)
and anti-FITC Alexa Fluor 488. In all cases, B cells were detected by
staining sections with Alexa Fluor 647-labeled anti-B220 (eBioscience).
Sections were mounted in Aqua-Poly Mount (Polysciences), examined on
a Zeiss LSM 510 system (Carl Zeiss) at The Rockefeller University Bio-
Imaging Resource Center, and analyzed with ImageJ (National Institutes
of Health).
Statistical analysis
Data were analyzed and charts were generated using Prism 5 GraphPad
software (San Diego, CA). The Student t test (between two groups or
conditions) was applied to compare statistical significance between
peptide-specific responses. A two-way ANOVA test was applied to com-
pare differences between treated group and control groups. Results were
considered statistically significant when p # 0.05.
Results
Treml4-deficient mice do not exhibit changes in the uptake and
cross-presentation of dying cells
We used gene targeting to generate Treml4 KO mice for these
studies. The targeting vector used to generate Treml4 KO mice
was constructed to replace exon 1 and 2 with a self-excising ACN
cassette (Fig. 1A). Correctly targeted ES cells were injected into
B6 blastocysts, followed by germline transmission of the mu-
tated allele (Fig. 1B–D). Treml4 KO mice were born at the ex-
pected Mendelian frequency, were fertile, and appeared to be
healthy over 6 mo of observation. Treml4 is primarily expressed
in the spleen (4), but Treml4 KO mice had normal numbers of
splenic leukocytes, including T cells, B cells, NK cells, gran-
ulocytes, monocytes, DCs, and red pulp macrophages (data not
shown).
To investigate the in vivo function of Treml4, we evaluated
whether Treml4 is involved in the uptake of dying cells and cross-
presentation of cell-associated Ags. B6 splenocytes were labeled
with CFSE, induced to undergo apoptosis by osmotic shock (21),
and then injected i.v. into wild-type (WT) littermates (Treml4+) or
Treml4 KO (Treml42/2) mice. Two hours later, the uptake of
CFSE+ cells by CD11chigh DCs was monitored by FACS. We
detected uptake of CFSE+ dying cells in CD8a+ classical DCs
in both WT littermates (Treml4+) and Treml4 KO (Treml42/2)
mice, and the frequency was not different between the strains
of mice, which suggested that Treml4 is not essential for up-
take of dying cells by DCs in vivo (Fig. 1E). To monitor Ag
cross-presentation in vivo, WT littermates or Treml4 KO mice
were injected i.v. with dying TAP2/2 splenocytes loaded with
OVA (TAP2/2/OVA) in the presence or absence of an adjuvant
(a-GalCer). After 7 d, Ag presentation and priming of OVA-
specific CD8+ T cells was monitored after in vitro restimulation
with OVA peptide in the presence of BFA and staining of intra-
cellular IFN-g. As shown in Fig. 1F and 1G, Ag-specific IFN-g–
producing CD8+ T cells were generated to comparable extents in
Treml4 KO (Treml42/2) mice as in control littermates (Treml4+),
indicating that cross-presentation was independent of Treml4 in
this system. Thus, Treml4 is not essential for uptake and cross-
presentation of dying cells in vivo.
FIGURE 2. mAb against Treml4 labels CD8a+ DCs, red pulp macrophages (RPM), and Ly6Clow monocytes. A, C57BL/6 (top panel), BALB/c (middle
panel), or CxB6 F1 (bottom panel) splenocytes were analyzed by multicolor flow cytometry for the expression of Treml4 in different subsets of leukocytes
(24). For control, we used rat IgG1 isotype control (blue graphs) or Treml4 KO mice on B6 background (gray graphs). B, CD115+ splenic monocytes from
B6 or Treml4 KO mice were further gated on the expression of Ly6C. Ly6Clow and Ly6Chigh monocytes were analyzed for the expression of Treml4. C, As
in B, but expression of Treml4 was evaluated in Ly6Chigh and Ly6Clow blood monocytes. In all cases, one experiment of two with similar results is shown.
PDCs, plasmacytoid DCs.
















Treml4 is mainly expressed on CD8a+ DCs, tissue
macrophages, and monocytes
To examine the pattern of expression of Treml4 in different mouse
tissues, we used a previously described multicolor flow cytometry
strategy that facilitates side-by-side evaluation of distinct splenic
leukocytes populations (15, 24). Consistent with our previous
results (4), Treml4 was abundantly expressed on splenic CD8a+
DCs and splenic red pulp macrophages of all mouse strains ana-
lyzed (C57BL/6, BALB/c, and CxB6 F1 mice) but not on B cells,
T cells, NK cells, or granulocytes (Fig. 2A). We found that splenic
CD8a2 DCs expressed low levels of Treml4, but plasmacytoid
DCs were negative for this receptor. As previously reported,
Treml4 was also found to be a good marker for Ly6Clow mono-
cytes both in the spleen and blood (Fig. 2B, 2C, respectively) (25).
Importantly, no staining with anti-Treml4 mAb was observed on
any leukocytes from Treml4 KO mice. Therefore, mouse Treml4
is highly expressed on CD8a+ DCs, spleen macrophages, and
Ly6Clow monocytes.
Injected anti-Treml4 mAb rapidly labels CD8a+ DCs, tissue
macrophages, and monocytes in mice
To assess whether specific targeting of anti-Treml4 mAb took place
in vivo, B6 or Treml4 KO mice were inoculated i.p. with 10 mg
Alexa Fluor 647-labeled mAb. The uptake of labeled mAb was
evaluated by multicolor flow cytometry, as above, 1 h postinoc-
ulation. The injected anti-Treml4 mAb labeled most CD8a+ DCs
and red pulp macrophages, but it only slightly labeled the CD8a2
DCs (Fig. 3A). This labeling was specific because none was ob-
served in Treml4 KO mice (Fig. 3A). In addition, Treml4 mAb was
taken up by splenic monocytes, especially Ly6Clow ones (Fig 3B).
Immunofluorescence staining of tissue sections showed high uptake
of anti-Treml4 mAb by CD169+ marginal metallophilic macro-
phages (Fig. 3C) but only weak capture by SIGNR1+ marginal zone
macrophages (Fig. 3D), which corresponds to the described ex-
pression of Treml4 by these macrophage populations (4). Alto-
gether, these results indicated that i.p. inoculation of anti-Treml4
mAb faithfully targets in vivo to cells that express the receptor.
FIGURE 3. Anti-Treml4 mAb is mainly captured by CD8a+ DCs, splenic macrophages, and Ly6Clow monocytes in vivo. A, B6 or Treml4 KO mice were
inoculated i.p. with 10 mg Alexa Fluor 647-labeled anti-Treml4 mAb. Uptake of labeled mAb by different splenic DC subsets and leukocyte populations
was evaluated 1 h after inoculation by multicolor flow cytometry (15). B, As in A, but two populations of CD11bhigh CD115+ splenic monocytes, Ly6Clow
(left panel) and Ly6Chigh (right panel), were further analyzed for the uptake of Alexa Fluor 647-labeled anti-Treml4 mAb. C and D, B6 or Treml4 KO mice
were inoculated i.p. with 25 mg purified anti-Treml4 mAb. Three hours postinoculation, dissected spleens were cryopreserved, sectioned, and stained with
anti-rat Alexa Fluor 555 (red) to detect the inoculated mAb. Marginal metallophilic macrophages (arrows) were identified by staining with anti-CD169 (C,
green), and marginal zone macrophages (dots) were identified by staining with anti-SIGNR1 (D, green). To identify B cell follicles (B), sections were
stained with B220 (blue). Scale bars, 100 mm. In all cases, one representative experiment of two or three with similar results is shown. PDCs, plasmacytoid
DCs; RP, red pulp; RPM, red pulp macrophage.
















Anti-Treml4 mAb delivers OVA Ag for efficient presentation
in vivo
To examine whether Treml4 could be used to enhance Ag pre-
sentation in vivo, we genetically engineered the H chain of the mAb
against Treml4 (32D11) (4) to express OVA. As previously de-
scribed (20), we added a tag sequence called OLLAS between the
H chain and the Ag to facilitate tracking of the mAb. For com-
parison, we used a previously described anti–DEC205-OVA mAb,
as well as a control Ig-OVA fusion mAb that has no receptor af-
finity (GL117) (20). The engineered H chains had a molecular
mass ∼110 kDa (Supplemental Fig. 1A) and reacted with anti-
mouse IgG1, anti-OVA, and anti-OLLAS by Western blotting
(Supplemental Fig. 1B) (20). By FACS, anti–Treml4-OVA bound
appropriately to CHO transfectants expressing Treml4 but not to
untransfected CHO/NEO cells (Supplemental Fig. 1C).
We used CD8+ OT-I and CD4+ OT-II transgenic T cells as
reporters to evaluate the capacity of Treml4 to mediate presenta-
tion of OVA through the MHC I and MHC II pathway. B6 mice
were injected s.c. with 3 mg anti–Treml4-OVA in the footpad
1 d after inoculating CFSE-labeled OT-I CD8+ T cells or OT-II
CD4+ T cells. After 3 d, spleen and skin-draining LNs were
evaluated for T cell proliferation by CFSE dilution. As shown
in Fig. 4, Treml4 mediated efficient Ag presentation to CD8+
T cells (Fig. 4A) and CD4+ T cells (Fig. 4B). Virtually all T cells
entered the cell cycle and underwent four to six cell divisions after
a single dose of anti–Treml4-OVA mAb, whereas control Ig-OVA
elicited no cell division. As quantified in Fig. 4C, anti–Treml4-
OVA Ag delivery was less efficient than was anti–DEC-OVA for
cross-presentation to CD8+ T cells (Fig. 4C, left panel) but was
more efficient for Ag presentation to CD4+ T cells (Fig. 4C, right
panel). Taken together, Treml4 efficiently brought about the pre-
sentation of OVA Ag on MHC I and MHC II products.
Treml4 HIV GAGp24 fusion mAb primes Th1 CD4+ T cells
To examine the capacity of anti-Treml4 mAb to immunize scarce
microbial-specific T cells in the polyclonal repertoire, we intro-
duced HIV GAGp24 (p24) by engineering the H chain. As controls,
we again used anti–DEC-p24, as well as a control Ig-p24 mAb
without receptor affinity, as previously described (15). As shown
in Supplemental Fig. 1, anti–Treml4-p24 had a molecular mass
∼75 kDa (Supplemental Fig. 1D), reacted with anti-mouse IgG1
and anti-p24 by Western blotting (Supplemental Fig. 1E), and
bound to CHO cells expressing the Treml4 receptor but not to
untransfected CHO/NEO cells (Supplemental Fig. 1F). Thus anti-
Treml4 mAb, like several other mAbs, can be successfully engi-
neered to express the HIV GAGp24 Ag.
To evaluate whether Treml4 could mediate priming of CD4+
T cells in vivo, we immunized B6 mice with 5 mg anti-Treml4-,
anti-DEC-, or control Ig- mAbs coupled with HIV GAGp24, along
with 25 mg anti-CD40 and 50 mg poly-IC as a maturation stimulus
or adjuvant. Two weeks after immunization, Ag-specific responses
were evaluated by production of IFN-g, TNF-a, and IL-2 in re-
sponse to HIV GAGp24 peptides by multicolor flow cytometry. As
shown in Fig. 5A–D, anti–Treml4-p24 induced significantly stron-
ger gag-specific T cell responses compared with control Ig-p24,
with frequencies .5–6% of IFN-g–, TNF-a–, and IL-2–produc-
ing CD3+ CD4+ T cells after a single i.p. injection. Importantly, this
Ag-specific response induced by delivery of p24 using anti-Treml4
mAb was entirely Treml4 receptor dependent, as shown by the lack
of CD4+ T cell priming when Treml4 KOmice were used (Fig. 5G).
To evaluate whether the immune CD4+ T cells could proliferate
in response to the reactive GAG peptide pool, we labeled spleno-
cytes with CFSE to follow the successive halving of CFSE/cell with
each division. CFSE-labeled splenocytes from mice primed for
2 wk with anti–Treml4-p24 in the presence of 25 mg anti-CD40 +
50 mg poly-IC were cultured for 4 d in the presence of p24 reactive
peptide or p17 nonreactive peptide, followed by challenge with p24
peptides. As illustrated in Fig. 5E, and quantified in Fig. 5F, the
T cells responded by proliferation and IFN-g production only to the
p24 peptide mix and not to the control p17 peptide mix. We con-
cluded that targeting vaccine proteins with anti-Treml4 mAb was
effective at initiating Th1 CD4+ T cell responses.
Similar results also were obtained when we used a prime/boost
regimen for immunization in the absence of anti-CD40 in B6 mice
(Supplemental Fig. 2).
Treml4 coupled with the breast cancer Ag HER2 elicits T cell
immunity and tumor protection
To examine whether Treml4 could mount an immune response
against the clinically relevant tumor Ag HER2, we genetically
FIGURE 4. Anti–Treml4-OVA induces in vivo pro-
liferation of CD8+- and CD4+-transgenic T cells. B6
mice were injected i.v. with 2–5 3 106 CFSE-labeled
OT-I (A) or OT-II (B) T cells and 24 h later with 3
mg control Ig-, anti–DEC-, and anti–Treml4-OVA fu-
sion mAbs s.c. in the footpad. Three days after mAb
inoculation, skin-draining LNs and spleen (SPL) were
harvested, and expansion of CD8+ or CD4+ Va2+
T cells was evaluated by FACS for CFSE dilution. The
percentage of transferred CD45.1+ T cells undergoing
more than one division is shown. Plots are gated on
CD4+ CD3ε+ T cells and are representative of three
experiments. C, As in A and B, but bar graphs represent
T cells undergoing more than one division (fold clonal
expansion; see Materials and Methods) as the mean 6
SD of four to six animals in three or four different
experiments.
















engineered anti-Treml4 to express the ECD of the breast cancer
protein HER2 (Wang et al., submitted for publication). SDS-PAGE
and Western blotting expectedly showed that the fusion H chain
was 120 kDa and that the fusion mAb reacted to both anti-mouse
IgG and anti-HER2 (data not shown). Also, similarly to anti-
Treml4 mAbs conjugated with OVA and HIV GAGp24, the fu-
sion mAb bound to CHO cells expressing Treml4 but not to CHO
NEO cells (data not shown).
To determine the immunogenicity of the anti–Treml4-HER2
mAb in vivo, FVB/N mice were immunized in a prime-boost
regimen consisting of two doses, administered 4 wk apart, of 5
mg anti–Treml4-HER2 mAb in the presence of 50 mg poly-IC.
Control groups were injected with control HER2 plus poly-IC,
poly-IC alone, or PBS alone. Two weeks after boosting, total
splenocytes were labeled with CFSE and restimulated with a
nonreactive peptide pool HIV GAGp24, the reactive peptide pool
HER2, and a cross-reactive peptide pool neu. Four days later,
splenocytes were restimulated for 6 h, as before, in the presence of
BFA and analyzed for intracellular cytokines by flow cytometry.
Both CD4+ and CD8+ T cells significantly proliferated and pro-
duced IFN-g after two doses of anti–Treml4-HER2 but not
with control HER2 mAb immunization (Fig. 6A, 6B). Thus, anti–
Treml4-HER2 mAb mediated Th1 CD4+ T cell responses, as well
as efficient cross-presentation and immunization of CD8+ T cells.
We extended the experiments to determine whether anti–
Treml4-HER2 could be used to induce an antitumor response in
vivo. We tested tumor protection in a neu-expressing mouse trans-
plantable-tumor model. In a different study, we showed that tar-
geting HER2 to DEC205 receptor was able to mediate efficient
tumor protection by a T cell-dependent mechanism (Wang et al.,
submitted for publication). To this end, we primed and boosted
FVB/N mice with anti–Treml4-HER2, along with poly-IC as an
adjuvant, as above. Ten days after the boost vaccination, mice
were injected with 1 3 106 neu-expressing NT2.5 tumor cells.
Mice were monitored for tumor growth every other day for 35 d.
As shown in Fig. 6C, mice that received anti–Treml4-HER2 mAb
showed significantly smaller tumor volumes compared with those
injected with control HER2, poly-IC alone, or PBS (p , 0.01)
(Fig. 6C). This protection was mediated by both CD4+ and CD8+
T cells, because depletion of either (or both) T cells strongly abol-
ished tumor protection (Fig. 6D). Thus, directing HER2 to Treml4-
expressing cells resulted in significant tumor protection in vivo.
Discussion
We used Ag targeting with anti-mouse Treml4 mAbs to determine
the capacity of this receptor for dying cells to mediate Ag pre-
sentation and immunization of naive mice. It was feasible to en-
gineer three proteins—OVA, HIV GAGp24, and the extracellular
FIGURE 5. Targeting Ag through Treml4 induces HIV GAGp24 Th1 responses in vivo. B6 mice were immunized with 5 mg anti-DEC205 or anti-Treml4
mAbs conjugated with HIV GAGp24 (p24) in the presence of 50 mg poly-IC and 25 mg anti-CD40 (Adj). A mAb conjugated with HIV GAGp24 without
receptor affinity was used as a control (control-p24). Fourteen days after inoculation, splenocytes were restimulated in vitro with HIV GAGp17 (p17,
negative control) or HIV GAGp24 peptide mix (p24) in the presence of BFA for 6 h. A, Intracellular staining was performed to detect the percentage of
IFN-g+ in CD3+ CD4+ gated T cells. B, Percentage of IFN-g+ CD4+ T cells is shown as mean6 SD of four to six experiments with two or three mice/group.
As in B, but TNF-a (C) and IL-2 (D) cytokine production was evaluated by intracellular cytokine staining in the CD3+ CD4+ gated T cells in response to
HIV GAGp17 or HIV GAGp24 peptide mix. Mean6 SD from two experiments with eight mice total is shown. E, Bulk splenocytes were labeled with CFSE
and stimulated with HIV GAGp24 peptide mix (p24) or control HIV GAGp17 peptide mix (p17) for 4 d, whereupon the cells were restimulated for 6 h
with HIV GAGp24 peptides in the presence of BFA to detect IFN-g in proliferated CFSElow T cells. Panels show the percentage of IFN-g+ or IFN-g2
CD3+ CD4+ proliferating T cells (top row and bottom row, respectively) from one of two similar experiments with four mice/group. F, As in E, but the
percentage of CFSElow IFN-g+ CD4+ T cells is shown as mean 6 SD of eight animals in two different experiments. G, B6 or Treml4 KO mice were
immunized with 5 mg anti-DEC205 or anti-Treml4 mAbs conjugated with HIV GAGp24 (p24) in the presence of 50 mg poly-IC and 25 mg anti-CD40 (Adj)
and analyzed 14 d later after restimulation in vitro with HIV GAGp17 (p17, negative control) or HIV GAGp24 peptide mix (p24) in the presence of BFA for
6 h. Percentage of IFN-g+ CD4+ T cells is shown as mean 6 SD of two experiments, with a total of four mice/group.
















domain of the oncogene HER2—into the H chain of cloned anti-
Treml4 mAbs. With OVA, we studied clonal expansion of CD4+
and CD8+ TCR-transgenic T cells 3 d after a s.c. dose of 3 mg
fusion mAbs was inoculated into the footpad. When we compared
Ag presentation after targeting OVA using anti-Treml4 or anti-
DEC mAbs, we found that anti–Treml4-OVA was more efficient
at inducing CD4+ T cell expansion, whereas anti–DEC-OVA was
more efficient for CD8+ T cells. Accordingly, anti–Treml4-OVA
was comparable in bringing about Ag presentation to another mAb
we studied that reacts with CD8a+ DCs (i.e., anti-langerin; data
not shown) (20). With HIV GAGp24 and HER2, we studied im-
munization of naive mice. For this to take place, it was necessary
to coadminister with the fusion mAb a stimulus for innate im-
munity; in our experiments, this was poly-IC administered alone
or in combination with anti-CD40. As in prior work on Ag tar-
geting to CD8a+ DCs via mAbs against DEC205, langerin, and
Clec9A (15), targeting to the Ig superfamily member Treml4
greatly enhanced immunity relative to a nonreactive Ig control.
The targeting was receptor specific, because immunization was
ablated in Treml4 KO mice.
Treml4 is an unusual receptor for dying cells, because it is
primarily expressed in spleen and not other lymphoid or non-
lymphoid tissues (4). The high expression in spleen was previously
attributed to high expression in red pulp macrophages and CD169+
marginal metallophilic macrophages (4). We extended the analysis
of Treml4 expression to a large panel of cell types in spleen. The
heightened expression on CD8a+ DCs and on macrophages was
confirmed. In addition, expression on splenic monocytes was
noted. Blood monocytes were also positive for Treml4, particu-
larly the Ly6Clow subset. However, peritoneal macrophages were
Treml42, as were liver and LN CD169+ sinus macrophages, as
documented in our initial report (data not shown) (4). Because
blood monocytes express this dying cell receptor, but spleen is the
main site for Treml4+ macrophages, we suspect the spleen sustains
Treml4 on monocytes that become splenic macrophages, whereas
other tissues do not. Alternatively, Ly6Clow monocytes may pri-
marily be giving rise to splenic, but not other, macrophages in the
steady state.
We did not detect major differences in immunization outcome
via Treml4 targeting relative to targeting DEC205, which is highly
expressed on the CD8a+ subset of DCs. Furthermore, Treml4 was
clearly able to mediate induction of an integrated and protective
CD4+ and CD8+ T cell response, as noted with HER2-specific
immune responses in FVB mice.
Treml4 is only one of several receptors that DCs express with the
potential to react with dying cells. Others include CD36 (26), aVb5
and aVb3 (27, 28), and CLEC 9A (29). Of note, these recep-
tors are specific for the CD8a+ DC subset, which, in contrast to
CD8a2 DCs, can selectively take up and present dying cells (Fig.
1) (30). CLEC9A has been studied most extensively for cross-
presentation of dying cell-associated Ags. The data showed that
CLEC9A is not required for phagocytosis but instead contributes
to cross-presentation following the uptake of dead cell-associated
Ags (29). In contrast, CD36, aVb5, and aVb3 do not appear to
FIGURE 6. Targeting breast cancer Ag HER2 to Treml4 elicits HER2-specific T cell immunity and tumor protection. FVB/N mice were primed and
boosted 4 wk apart with 5 mg anti–Treml4-HER2 fusion mAb in the presence of 50 mg poly-IC. As a control, we used a mAb without receptor specificity
(control HER2 mAb), poly-IC alone, or PBS. Fourteen days after boost, total splenocytes were labeled with CFSE and restimulated in vitro with a non-
reactive HIV GAGp24 (p24) peptide pool, a reactive HER2 peptide pool, or a cross-reactive NEU peptide pool. After 4 d, the cells were further stimulated
for 6 h, as before, in the presence of BFA, and cytokines were detected by intracellular staining. Data are the percentage of CFSElow IFN-g+ CD4+ (A) or
CD8+ (B) cells shown as two experiments with three mice/group. C, Fourteen days after boost, mice were injected with 13 106 NT2.5 transplantable breast
cancer cells s.c. into mammary fat pads. Data show the tumor volume over time as the mean of 5–10 mice/group (naive and Adj = 5 mice; control HER2
and anti–Treml4-HER2 = 10 mice) in two representative experiments. Significant differences were found between anti-Treml4 and the control groups (p ,
0.01). D, As in C, but 9, 6, and 3 d prior to tumor challenge, groups of mice were inoculated i.p. with anti-CD4–depleting mAb (GK1.5), anti-CD8–
depleting mAb (2.43), or isotype-control mAb (GL117). Mice were challenged with 1 3 106 NT2.5 tumor cells at day 14. Data are shown as the mean of
five animals/group in one representative experiment.
















contribute to the superior cross-presentation abilities of CD8a+
DCs (31). We were unable to detect alterations in either uptake or
cross-presentation of cell-associated OVA in Treml4 KO mice
relative to WT mice. This result suggested overlapping function
between Treml4 and other dying cell uptake receptors in vivo.
Alternatively, it is possible that dying cells used in experimental
studies are not the best physiological representatives of dying cells
in vivo.
As of now, a human anti-Treml4 mAb has not been produced.
Thus, the function of this molecule and its clinical application in
humans remains unclear. According to sequencing data (GenBank),
the human Treml4 gene contains a stop codon in the transmem-
brane region, which could be consistent with its release as a sol-
uble protein (4). Treml4 also shares functional similarities with
another Trem family member, Trem2; although the expression of
Treml4 has not been mapped in humans, Trem2 is known to be
expressed on human macrophages and monocyte-derived DCs (4).
It was also shown that mouse Trem2 is involved in the clearance
of apoptotic neurons by microglia (8). Likewise, we reported that
soluble Treml4 has a strong affinity for dead cells, suggesting
a functional similarity between the respective molecules (4).
Therefore, it is possible that Trem2 and Treml4 may have com-
pensatory functions, warranting further studies of both molecules
in humans.
C-type lectin-like receptors have been emphasized for receptor-
mediated Ag targeting within mAbs. Treml4 is unique, in that it
belongs to the Ig superfamily. The use of mAb-based Ag targeting
allowed the faithful delivery of Ag to the cells that express the
receptor (i.e., Treml4), and it enabled an assessment of the ability of
that receptor to enhance Ag presentation and immunization in an
intact animal. Specifically, we showed that a receptor previously
documented to engage with necrotic cells can capture, present Ags,
and, in the presence of an innate stimulus like poly-IC, induce Th1
CD4+ and CD8+ T cell immunity that promotes tumor protection.
Acknowledgments
We thank J. Adams for graphics andM. Nulty and A. Gottfried for help with
the manuscript.
Disclosures
The authors have no financial conflicts of interest.
References
1. Cambi, A., and C. Figdor. 2009. Necrosis: C-type lectins sense cell death. Curr.
Biol. 19: R375–R378.
2. Poon, I. K., M. D. Hulett, and C. R. Parish. 2010. Molecular mechanisms of late
apoptotic/necrotic cell clearance. Cell Death Differ. 17: 381–397.
3. Steinman, R. M., and H. Hemmi. 2006. Dendritic cells: translating innate to
adaptive immunity. Curr. Top. Microbiol. Immunol. 311: 17–58.
4. Hemmi, H., J. Idoyaga, K. Suda, N. Suda, K. Kennedy, M. Noda, A. Aderem,
and R. M. Steinman. 2009. A new triggering receptor expressed on myeloid cells
(Trem) family member, Trem-like 4, binds to dead cells and is a DNAX acti-
vation protein 12-linked marker for subsets of mouse macrophages and dendritic
cells. J. Immunol. 182: 1278–1286.
5. Klesney-Tait, J., I. R. Turnbull, and M. Colonna. 2006. The TREM receptor
family and signal integration. Nat. Immunol. 7: 1266–1273.
6. Ford, J. W., and D. W. McVicar. 2009. TREM and TREM-like receptors in in-
flammation and disease. Curr. Opin. Immunol. 21: 38–46.
7. Bouchon, A., F. Facchetti, M. A. Weigand, and M. Colonna. 2001. TREM-1
amplifies inflammation and is a crucial mediator of septic shock. Nature 410:
1103–1107.
8. Takahashi, K., C. D. Rochford, and H. Neumann. 2005. Clearance of apoptotic
neurons without inflammation by microglial triggering receptor expressed on
myeloid cells-2. J. Exp. Med. 201: 647–657.
9. Hamerman, J. A., J. R. Jarjoura, M. B. Humphrey, M. C. Nakamura,
W. E. Seaman, and L. L. Lanier. 2006. Cutting edge: inhibition of TLR and FcR
responses in macrophages by triggering receptor expressed on myeloid cells
(TREM)-2 and DAP12. J. Immunol. 177: 2051–2055.
10. Turnbull, I. R., S. Gilfillan, M. Cella, T. Aoshi, M. Miller, L. Piccio,
M. Hernandez, and M. Colonna. 2006. Cutting edge: TREM-2 attenuates mac-
rophage activation. J. Immunol. 177: 3520–3524.
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